Table 1.
Characteristics of participants with acute HCV infection in the InC3 Study (n=632)
| Overall (n=632), n (%)† | Spontaneous Clearance (n=173), n (%)‡ | |
|---|---|---|
| Site | ||
| UFO (United States) | 115 (18) | 31 (27) |
| ATAHC (Australia) | 119 (19) | 27 (23) |
| BAHSTION (United States) | 49 (8) | 14 (29) |
| BBAASH (United States) | 114 (18) | 41 (36) |
| HEPCO (Canada) | 75 (12) | 16 (21) |
| HITS-c (Australia) | 10 (2) | 3 (30) |
| HITS-p (Australia) | 89 (14) | 17 (19) |
| N2 (Australia) | 17 (3) | 4 (24) |
| ACS (the Netherlands) | 44 (7) | 20 (45) |
| Median age, yrs (IQR)* | 26 (23–32) | 26 (23–30) |
| Age, categorized* | ||
| <30 years | 403 (64) | 122 (30) |
| 30–39 years | 103 (16) | 28 (27) |
| ≥40 years | 75 (12) | 14 (19) |
| Missing | 51 (8) | 9 (18) |
| Female Sex# | 228 (36) | 86 (38) |
| Ethnicity | ||
| Caucasian | 516 (82) | 141 (27) |
| Aboriginal | 32 (5) | 10 (31) |
| Asian | 12 (2) | 3 (25) |
| Black | 24 (4) | 4 (17) |
| Other | 48 (8) | 15 (31) |
| History of injecting drug use | 608 (96) | 165 (27) |
| Symptomatic HCV infection* | ||
| No | 111 (18) | 15 (14) |
| Yes | 138 (22) | 37 (27) |
| Unknown | 383 (61) | 121 (32) |
| IL28B genotype (rs12979860) | ||
| TT | 63 (10) | 15 (24) |
| CT | 213 (34) | 46 (22) |
| CC | 266 (42) | 98 (37) |
| Missing | 90 (14) | 14 (16) |
| HIV infection* | ||
| No | 531 (84) | 147 (28) |
| Yes | 29 (5) | 7 (24) |
| Missing | 72 (11) | 19 (26) |
| HCV genotype* | ||
| Genotype 1 | 297 (47) | 79 (27) |
| Genotype 2 | 32 (5) | 7 (22) |
| Genotype 3 | 183 (29) | 33 (18) |
| Genotype 4 | 7 (1) | 1 (14) |
| Genotype 6 | 4 (1) | 0 (0) |
| Mixed genotype | 14 (2) | 2 (14) |
| Unknown genotype | 95 (15) | 51 (54) |
†
Percentages indicate column percentages,
‡
Percentages indicate row percentages,
*
At the time of incident HCV infection,
#
Includes 2 missing.
UFO, UFO STUDY; ATAHC, Australian Trial in Acute Hepatitis C; BAHSTION, Boston Acute HCV Study: Transmission, Immunity and Outcomes Network; BBAASH, Baltimore Before and After Acute Study of Hepatitis; HEPCO, St. Luc Cohort, HEPCO; HITS-c, Hepatitis C Incidence and Transmission Study-Community; HITS-p, Hepatitis C Incidence and Transmission Study-Prison; N2, Networks 2; ACS, Amsterdam Cohort Studies.